Additional file 1: of A new paradigm evaluating cost per cure of HCV infection in the UK

Supplementary material. (DOCX 39 kb

Additional file 1: of Hepatitis C – Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial

HepCATT study algorithm (Read codes). (DOC 118 kb

Dot plots of the mean OD autoantibody signal received from each serum sample against 9 TAAs.

<p>NY-ESO-1, p53, H-RAS-1 and RalA (A), FASN, AFP, Gankyrin and Survivin (B) and KOC, p62, GPC-3 and Alpha-enolase (C). Data for each antigen is shown as cancer then matched control. Error bars signify the mean with 95% confidence interval. Circled data points identify positive HCC responses.</p

Comparison of individual antigen specificities and sensitivities.

<p>Data shown for 96 cancers (% sensitivity), 96 matched normal sera (% specificity) and at risk sera (% positivity). Study 1: Data from initial screen of 41 antigens. Study 2: Data from the 21 lead antigens. Individual cut-offs for each antigen were applied to maximise cancer: normal differentiation.</p><p>TAA – tumor-associated antigens. n/a – not assessed.</p><p>Rejected antigens  =  Vitronectin; Survivin; KOC; p62; α-enolase; c-myc; GBU4-5, β-Catenin 1; CAGE; HuD; H-RAS-2; PRDX6; IMP1; K-RAS; MAGE-A4; MAGE-C2; SOX2; SSX1; VEGF-C; WT1-c-terminal.</p

Sample Cohort Information.

<p>HBV  =  Hepatitis B Virus, HCV  =  Hepatitis C Virus, ALD  =  Alcoholic Liver Disease, Other  =  Primary Biliary Cirrhosis, Autoimmune Hepatitis, Haemochromatosis, 1 or more aetiologies, no underlying liver disease, U/K  =  Unknown.</p

Dot plots of the mean OD autoantibody signal received from each serum sample from all four cohorts, against 4 TAAs.

<p>(NY-ESO-1 (A), p53 (B), Gankyrin (C) and Cyclin-B1 (D). Error bars signify the mean with 95% confidence interval. Circled data points identify positive HCC responses. Horizontal lines above data sets indicate the OD value of mean plus 2SD of the normal control cohort.</p

Comparisons of specificity and sensitivity in 5 different TAA panels.

<p>Panel composition was as follows:1 =  H-RAS-1;4 =  H-RAS-1 + p16 + Gankyrin + NY-ESO-1;8 =  Panel 4 + Sui1, p53, RalA, CyclinB1;12 =  Panel 8 + HCC1, WT1-n-term, CK8, AFP;21 =  Panel 12 + β-Catenin2, β-HCG, HDGF, Calreticulin, GRP78, FASN, GPC-3, DKK1, l-myc-2.</p